Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab(®))

The trifunctional antibody (trAb) catumaxomab is characterized by a unique ability to bind three different cell types: tumor cells; T-cells; and accessory cells. It binds to epithelial cell adhesion molecule (EpCAM) on tumor cells, the CD3 antigen on T-cells, and to type I, IIa, and III Fcγ receptor...

Descripción completa

Detalles Bibliográficos
Autor principal: Seimetz, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119393/
https://www.ncbi.nlm.nih.gov/pubmed/21716847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119393/
https://www.ncbi.nlm.nih.gov/pubmed/21716847

Ejemplares similares